FDA approves GSK RSV vaccine for adults 50 to 59
A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.Hannah Mckay | ReutersThe Food and Drug Administration on Friday expanded the approval of GSK's respiratory syncytial virus vaccine to...